Serbia

Population 2018: 8.8 million

Tuberculosis profile

Estimates of TB burden*, 2018

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>1.5 (1.3–1.8)</td>
<td>17 (15–20)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>&lt;0.01 (&lt;0.01–&lt;0.01)</td>
<td>0.06 (0.03–0.09)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>0.022 (0.01–0.039)</td>
<td>0.25 (0.11–0.45)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.055 (0.05–0.061)</td>
<td>0.63 (0.57–0.69)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0 (0–&lt;0.01)</td>
<td>0.01 (0–0.02)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases: 1.1% (0.49–2.2)  Previously treated cases: 4.7% (1.3–11)

TB case notifications, 2018

Total new and relapse: 1 330

- % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status: 4%
  - % pulmonary: 81%
  - % bacteriologically confirmed**: 72%
  - % children aged 0-14 years: 2%
  - % women: 45%
  - % men: 53%

Total cases notified: 1 358

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018: 87% (75–100)

TB patients facing catastrophic total costs: 4% (3–4)

TB case fatality ratio (estimated mortality/estimated incidence), 2018: 3% (2–4)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive: 8 14%
  - on antiretroviral therapy: 8 100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance**:
  - New cases: 56%
  - Previously treated cases: 40%

Laboratory-confirmed cases*

Patients started on treatment**

MDR/RR-TB cases tested for resistance to second-line drugs

Treatment success rate and cohort size

New and relapse cases registered in 2017: 86% 1 440

Previously treated cases, excluding relapse, registered in 2017: 56% 18

MDR/RR-TB cases registered in 2017: 75% 8

MDR/RR-TB cases started on second-line treatment in 2016: 70% 10

XDR-TB cases started on second-line treatment in 2016: 0% 1

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment: 75%

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 2%

TB financing, 2019

National TB budget (US$ millions): 8.2

Funding source: 96% domestic, 0% international, 1% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-01-24

Data: www.who.int/tb/data